For instance, developing CD146‐targeted radioimmunotherapy (RIT) for effective melanoma treatment is possible, if YY146 is radiolabeled with either beta‐emitting therapeutic radionuclide (such as 90Y, 177Lu, and 188Re),44, 45 or alpha‐emitting radionuclide (such as 211At, 225Ac, and 213Bi).38, 46 CD146‐targeted RIT will hopefully lead to tumor‐specific lethal DNA damage and enhanced immune responses.47 While PIT is a viable option for localized subcutaneous melanomas, radioconjugates targeting CD146 will be of great value for advanced and metastatic melanomas. This evidence concerns the gene MCAM and metastatic melanoma.